The current trial is only for toxicity and tolerability, any update would be about any adverse conditions caused, good news will probably give a minor boost, but bad news the MMs will give us a kicking. The only news that will give us a serous boost is efficacy that trial does not start till the middle of the year so we won't be getting any updates about efficacy till around February next year.
Not at all. We are due an update in less than 6 weeks. We could get news before that. The share seems significantly undervalued at these levels, a view backed up by the broker note last week. It's just a matter of time...
Interesting insights and reiteration of the potentially massive scale of the CHK1 market, along with caveats regarding pricing issues!
"If there was any doubt that the oncology market is set to reach unprecedented heights, FiercePharma's top 15 list of cancer drugs in 2022 should eliminate it.
All told, by 2022, the top 15 cancer drugs are expected to collectively make almost $90 billion in sales. To put that in perspective, that represents about one-fourth of the entire U.S. pharma market in 2014, according to QuintilesIMS data. It's also bigger than pharma's haul in Japan or China that year.
It will likely be no revelation that three drugs among the top six on our list—provided courtesy of EvaluatePharma and Chempetitive—come from the highly touted PD-1/PD-L1 or checkpoint inhibitor class.
This brand-new category of cancer drugs works by activating the immune system, enabling it to recognize cancer cells and destroy them. The class has achieved unprecedented efficacy in a broad range of cancers and provides a much-needed new treatment approach alongside chemotherapy and targeted cancer drugs, which tend to lose efficacy over time".
Minden, I'm sure 2017 will different for us and new level in be break this year Mate. Let's wait Mate, I've enough here to make me happy and I believe You and others will be as well. Good luck to you & all here. Obelix
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.